TherapeuticsMD, Inc. (NYSEMKT:TXMD) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On May 2, 2017, TherapeuticsMD, Inc. issued a press release
announcing its results of operations for its first fiscal quarter
ended March 31, 2017. A copy of the press release is furnished as
Exhibit 99.1 hereto and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including the
exhibit) is furnished to Item 2.02 and shall not be deemed to be
filed for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section. The information in this
Current Report shall not be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date of this
Current Report, regardless of any general incorporation language
in the filing.
We do not have, and expressly disclaim, any obligation to release
publicly any updates or any changes in our expectations or any
change in events, conditions, or circumstances on which any
forward-looking statement is based.
The text included with this Current Report on Form 8-K is
available on our website located at www.therapeuticsmd.com,
although we reserve the right to discontinue that availability at
any time.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit Number |
Description | ||
| 99.1 |
Press Release from TherapeuticsMD, Inc., dated May 2, 2017, entitled TherapeuticsMD Announces First Quarter 2017 Financial Results. |
About TherapeuticsMD, Inc. (NYSEMKT:TXMD)
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew. TherapeuticsMD, Inc. (NYSEMKT:TXMD) Recent Trading Information
TherapeuticsMD, Inc. (NYSEMKT:TXMD) closed its last trading session down -0.20 at 4.81 with 3,229,999 shares trading hands.